RDS is a disease process that results from an absent or diminished amount of surfactant in the newborn lung. Prematurity, therefore, plays a crucial role in the development of RDS. The incidence is ...

The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant ...

SURFAXIN is the First FDA-Approved Synthetic, Peptide-Containing Surfactant WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology ...

HealthDay News — The FDA has approved Surfaxin (lucinactant) to prevent respiratory distress syndrome (RDS) in premature infants. Premature infants born before 37 weeks’ gestation often cannot produce ...

Higher body mass index (BMI) at the start of pregnancy is associated with increased risk for adverse maternal outcomes, including preeclampsia, and neonatal complications, such as respiratory distress ...

Newborns who lack natural surfactants develop respiratory distress syndrome. Surfactants are materials that reduce liquid surface tension, enabling carbon dioxide and oxygen to easily exchange as ...